INVESTORS / Corporate Governance


Laurus Labs is committed to conducting its business with the highest standards of integrity, with the Board providing indispensable leadership.

The corporate governance framework at Laurus Labs is based on an effective independent Board, separation of the Board’s supervisory role from the executive management team, constitution of the Board committees and formulation of policies, each as required under law, including SEBI Listing Regulations.

We comply fully with the requirements of applicable regulations, including the SEBI Listing Regulations, the Companies Act, and the SEBI ICDR Regulations, in respect of corporate governance. Currently, the board has 10 Directors, headed by the Chairman who is a non-executive and independent director.

We have four Executive Directors, six Non-Executive Directors including five Independent Directors on the Board. Our Board also has one woman Director. The Board functions directly or through various committees constituted to oversee specific operational areas. The executive management reports regularly on the company’s performance.



Dr. M Venu Gopala Rao
Non-Executive Chairman/Independent Director


Dr. Chava Satyanarayana
CEO/Executive Director


Dr. Lakshman Chunduru
Executive Director – Quality


Mr. Venkata Ravi Kumar Vantaram
CFO/ Executive Director


Mr. Chandrakanth Chereddi
Non-Executive Director


Mr. Narendra Ostawal
Non-Executive Director/Nominee Director


Mrs. Aruna Bhinge
Non-Executive Director/Independent Director


Mr. Rajesh Koshy Chandy
Non-Executive Director/Independent Director


Dr. Ravindranath Kancherla
Non-Executive Director/Independent Director




FY-2021



FY-2020


FY-2019



FY-2018



FY-2017


During the year, the Company has inducted three independent directors on the Board. The Company has arranged a special induction/familiarization program to these three directors wherein these three directors have made a two-day visit in November 2016 to its Corporate Office and its R&D Plant at Hyderabad, its manufacturing facilities at Visakhapatnam and interacted with all senior colleagues including the whole time directors of the Company. During March 2017 also once again the Board meeting was conducted in Visakhapatnam and the Directors have visited all the manufacturing facilities of the Company. At the time of appointment, the CEO and some other Board members have interacted with these new independent directors and explained the objective and philosophy and core values of the Company. The Company has provided all the literature such as its previous annual reports, presentation on operations, budget vs. achievements etc. All these independent directors have been provided with the letters of appointments wherein their duties, roles and expectations of the Company etc. have been clearly specified.


Apart from the above, senior management personnel of the Company regularly make presentations to the Board members on the operations of the Company, its plans, strategy, risks involved, new initiatives etc. and seek their views and suggestions on the same. The Board members have been provided with various policies of the Company including Code of Conduct for Directors and Senior Management Personnel etc.

Discover more

Annual Report

We are making great progress on our strategic goals. See our latest annual report.

Download

Find out more about us

Strengths & Strategy

We are building on our strengths to further extend our product portfolio and target fast-growing segments.

Research & Development

As a science-led pharmaceutical company, we invest in cutting-edge research to develop new cures for challenging diseases.

Corporate Sustainability

As a responsible corporate citizen, we will conduct our business with complete respect for the environment and community.

ABOUT US

Business units

INVESTORS

Connect